UK pharma firm Clinigen opens Japan office to boost Asia presence

UK pharma firm Clinigen Group plc has opened an office in Tokyo and set up Clinigen KK, a move to strengthen its presence in Asia after the acquisition of Asia and Africa focused pharma firm Link Healthcare last year.

Announcing the launch of its business in Japan in a statement today, Clinigen said that alongside the launch, Clinigen KK will transfer the marketing authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from its Japanese distribution partner Nobel Pharma on November 1.

Last year, London-based Clinigen acquired Link Healthcare a specialist pharmaceutical and medical technology business focussed on the Asia, Africa and Australasia region for an initial consideration of $54.7 million (£44.5 million) and a maximum of approximately $122.9 million (£100 million) based on achievement of milestones.

Clinigen’s product Foscavir is a medicine indicated to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients. Japan was the first market where Clinigen successfully achieved a new license extension for HSCT patients in 2011.

“Japan remains an important market for Foscavir with more than 2,000 patients treated annually. Clinigen will assume full marketing and distribution responsibility for Foscavir from November, to supply the product to healthcare professionals and patients across Japan,” the company said.

“The opening of our Japanese business helps support our goals and will enable us to effectively serve the Japanese market by supplying our own products, beginning with Foscavir,” Clinigen CEO Shaun Chilton said.

At a time when many pharmaceutical and biotechnology companies are looking for specialist partners to work with them in Asia, the opening of the firm’s Japanese office gives it more opportunities to provide customers with its global expertise combined with local knowledge, he added.

Japan is the second largest pharmaceutical market globally and the Japanese business will allow the company to supply and distribute both licensed and unlicensed medicines in the country.

Also Read:

Singapore-based Eywa Pharma raises $30m from Fidelity, F-Prime Capital Partners

Japan’s Takeda Pharmaceutical on hunt for overseas deals

China Resources Pharma attracts Reckitt, Fujifilm to Hong Kong IPO

Chinese PE firm CSC inks multimillion deal with UK’s Founders Factory to invest in AI startups

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.